These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8277912)

  • 1. Piperacillin/tazobactam.
    Med Lett Drugs Ther; 1994 Jan; 36(914):7-9. PubMed ID: 8277912
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of piperacillin/tazobactam in skin and soft tissue infections.
    File TM; Tan JS
    Eur J Surg Suppl; 1994; (573):51-5. PubMed ID: 7524796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of piperacillin/tazobactam in intra-abdominal infections.
    Vestweber KH; Grundel E
    Eur J Surg Suppl; 1994; (573):57-60. PubMed ID: 7524797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of piperacillin/tazobactam in the treatment of experimental intra-abdominal infections.
    Nord CE; Lahnborg G
    Eur J Surg Suppl; 1994; (573):45-9. PubMed ID: 7524795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic activity of piperacillin: YTR-830H combinations in vitro and in vivo.
    Kuck NA; Petersen PJ; Weiss WJ; Jacobus NV; Testa RT; Tally FP
    J Chemother; 1989 Jul; 1(4 Suppl):105-6. PubMed ID: 16312325
    [No Abstract]   [Full Text] [Related]  

  • 6. [A combined dosage form of piperacillin and tazobactam--tazocin].
    Iakovlev SV
    Antibiot Khimioter; 1997; 42(2):5-16. PubMed ID: 9124994
    [No Abstract]   [Full Text] [Related]  

  • 7. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
    Li C; Kuti JL; Nightingale CH; Mansfield DL; Dana A; Nicolau DP
    J Antimicrob Chemother; 2005 Aug; 56(2):388-95. PubMed ID: 16002420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacterial susceptibilities to piperacillin/tazobactam in a tertiary care hospital: 5-year review.
    Platsouka E; Zissis NP; Portolos J; Paniara O
    J Chemother; 2003 Feb; 15(1):27-30. PubMed ID: 12678410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections.
    Mouton Y; Leroy O; Beuscart C; Chidiac C; Senneville E; Ajana F; Lecocq P
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():87-95. PubMed ID: 8383658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piperacillin-Tazobactam: a new beta-lactam-beta-lactamase inhibitor combination.
    Daniel KP; Krop LC
    Pharmacotherapy; 1996; 16(2):149-62. PubMed ID: 8820460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
    Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
    Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Multicentre clinical trial on efficacy and safety of domestic piperacillin/tazobactam for treatment of acute bacterial infections].
    Liu Y; Wang R; Yu B
    Zhonghua Yi Xue Za Zhi; 2001 Jan; 81(1):41-4. PubMed ID: 11798851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In the literature. Piperacillin-tazobactam and extended-spectrum β-lactamase--producing Escherichia coli.
    Clin Infect Dis; 2013 Nov; 57(10):iii-iv. PubMed ID: 24308040
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination beta-lactam and beta-lactamase-inhibitor therapy: pharmacokinetic and pharmacodynamic considerations.
    Dudley MN
    Am J Health Syst Pharm; 1995 Mar; 52(6 Suppl 2):S23-8. PubMed ID: 7606586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and tissue penetration of piperacillin/tazobactam with particular reference to its potential in abdominal and soft tissue infections.
    Sörgel F; Kinzig M
    Eur J Surg Suppl; 1994; (573):39-44. PubMed ID: 7524794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The sensitivity of clinical isolates of anaerobic species to piperacillin-tazobactam and other antimicrobial agents.
    Namavar F; Severin WP; Stobberingh E; Smeets T; MacLaren DM
    J Antimicrob Chemother; 1994 Sep; 34(3):415-9. PubMed ID: 7829416
    [No Abstract]   [Full Text] [Related]  

  • 17. Piperacillin/tazobactam compared with cefuroxime/ metronidazole in the treatment of intra-abdominal infections.
    Ohlin B; Cederberg A; Forssell H; Solhaug JH; Tveit E
    Eur J Surg; 1999 Sep; 165(9):875-84. PubMed ID: 10533765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Laboratory and clinical studies on tazobactam/piperacillin in the field of pediatrics].
    Kuno K; Ogawa A; Hayakawa F; Miyajima Y; Takahashi H; Okumura A; Kato T; Itomi K
    Jpn J Antibiot; 1998 Jun; 51(6):395-406. PubMed ID: 9755829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Piperacillin-tazobactam versus ciprofloxacin plus amoxicillin in the treatment of infective episodes after liver transplantation.
    Philpott-Howard J; Burroughs A; Fisher N; Hastings M; Kibbler C; Mutimer D; Patch D; Rolando N; Wade J; Wendon J; O'Grady J
    J Antimicrob Chemother; 2003 Dec; 52(6):993-1000. PubMed ID: 14585863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro susceptibility of Acinetobacter baumannii to biapenem, piperacillin/tazobactam and thirteen other antimicrobial agents.
    Simor AE; Louie L; Louie M
    Eur J Clin Microbiol Infect Dis; 1994 Jun; 13(6):521-3. PubMed ID: 7957281
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.